We are live on ! Find out more
CSBR icon

Champions Oncology
CSBR

45 hedge funds and large institutions have $47.2M invested in Champions Oncology in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

22% more funds holding

Funds holding: 37 → 45 (+8)

1.17% more ownership

Funds ownership: 51.44% → 52.61% (+1.2%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

53% less capital invested

Capital invested by funds: $100M → $47.2M (-$52.8M)

Holders
45
Holders Change
+8
Holders Change %
+21.62%
% of All Funds
1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
15
Increased
14
Reduced
11
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Cadence Capital Management
Massachusetts
+$1.41M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$798K
3
Allianz Asset Management
Allianz Asset Management
Germany
+$743K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$603K
5
Invesco
Invesco
Georgia
+$596K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$2.16M
2
Deutsche Bank
Deutsche Bank
Germany
-$748K
3
VF
Virtu Financial
New York
-$642K
4
GIP
Granite Investment Partners
California
-$427K
5
OC
Oppenheimer & Co
New York
-$344K
Name Holding Trade Value Shares
Change 		Change in
Stake
SSB
26
Sandy Spring Bank
Maryland
$205K +$301K +26,250 New
Squarepoint
27
Squarepoint
New York
$185K +$272K +23,659 New
Arrowstreet Capital
28
Arrowstreet Capital
Massachusetts
$179K +$114K +9,959 +77%
OAM
29
Oxford Asset Management
United Kingdom
$165K +$242K +21,075 New
Millennium Management
30
Millennium Management
New York
$119K -$117K -10,173 -40%
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$112K – – –
Morgan Stanley
32
Morgan Stanley
New York
$112K +$119K +10,324 +253%
Deutsche Bank
33
Deutsche Bank
Germany
$78K -$748K -65,147 -87%
PCM
34
Prelude Capital Management
New York
$46K +$67.8K +5,900 New
PAM
35
Panagora Asset Management
Massachusetts
$19K +$27.8K +2,422 New
AG
36
Advisor Group
Arizona
$17K +$18.4K +1,600 +276%
Wells Fargo
37
Wells Fargo
California
$16K -$40.2K -3,500 -64%
VIMU
38
Veritas Investment Management (UK)
United Kingdom
$16K – – –
LTFS
39
Ladenburg Thalmann Financial Services
Florida
$8K -$7.6K -662 -41%
TRCT
40
Tower Research Capital (TRC)
New York
$8K +$12K +1,044 New
Macquarie Group
41
Macquarie Group
Australia
$7K +$10.3K +900 New
IA
42
IFP Advisors
Florida
$6K -$9.19K -800 -53%
Federated Hermes
43
Federated Hermes
Pennsylvania
$5K +$1.8K +157 +31%
APC
44
Aspire Private Capital
North Carolina
$5K +$7.64K +665 New
UBS Group
45
UBS Group
Switzerland
$3K -$49.5K -4,312 -92%
JP Morgan Chase
46
JP Morgan Chase
New York
– -$2.16M -123,770 Closed
VF
47
Virtu Financial
New York
– -$642K -36,751 Closed
OC
48
Oppenheimer & Co
New York
– -$344K -19,715 Closed
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
– -$178K -10,214 Closed
DWA
50
Dorsey Wright & Associates
California
– -$20K -1,159 Closed
1
2

CSBR Hedge Fund Activity: Q4 2018 in Review

45 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q4 2018, worth a combined $47.2M — down 53% from $100M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CSBR positions and 6 closed out — a net gain of 9 holders — while 14 added to existing stakes and 11 trimmed.

The largest buyer was Cadence Capital Management, opening a new position worth an estimated $1.41M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.16M sold.

  • 45 institutional investors held Champions Oncology (CSBR) as of Q4 2018, up from 37 in Q3 2018.
  • Funds reported $47.2M of Champions Oncology stock for Q4 2018, down 53% quarter-over-quarter.
  • 15 funds opened new Champions Oncology positions in Q4 2018 and 6 closed out, a net change of +9 holders.
  • The largest Champions Oncology buyer in Q4 2018 was Cadence Capital Management, an estimated $1.41M added.
  • The largest Champions Oncology seller in Q4 2018 was JP Morgan Chase, an estimated $2.16M sold.

Based on aggregated 13F filings for Q4 2018.